NR2F6 and melanoma: To evaluate the contribution of CD4+ and CD8+ T cells to the observed decreased tumor outgrowth, we challenged Nr2f6−/− subcutaneously with 1×105 B16-OVA melanoma cells and treated them with CD4+ and CD8+ depleting antibodies.